The authors prospectively studied 24 consecutive cases of neuroleptic
malignant syndrome occurring in 20 patients in a general hospital over a
6-year period. They present detailed data concerning the clinical setting
in which neuroleptic malignant syndrome occurs, the associated clinical and
laboratory features, the favorable outcome that can be achieved with
vigorous supportive therapy, and the factors that might help predict
whether patients with neuroleptic malignant syndrome will subsequently be
able to tolerate the reintroduction of neuroleptic medication.